Timothy Cripe P MD, PhD


Timothy Cripe P MD, PhD
ProfessorCollege of Medicinetimothy.cripe@nationwidechildrens.org
700 Childrens Dr Columbus OH 43205
Phone:(614) 722-3552Fax: (614) 722-3699
  • Translational Therapeutics

General Research Interest

Oncolytic virotherapy, targeted small molecule inhibitors, non-CNS solid tumors in children

Research Description

My laboratory is interested in developing and studying targeted therapeutics for non-CNS solid tumors in children, particularly sarcomas and neuroblastoma. Our efforts are primarily focused on the development of oncolytic virotherapy as well as small molecule targeted inhibitors. Active projects include studies of the mechanism and enhancement of tumor-selective virus delivery for metastatic disease, the role and manipulation of regulatory T cells in the antiviral and antitumor immune response, the utility of incorporating therapeutic transgenes to modify the tumor microenvironment, the effect of small molecule inhibitors combined with oncolytic virus infection, and the effect of oncolytic viruses on cancer stem cells.  

Transinstitutional Work

We have ongoing collaborations with Drs E.A. Chiocca and B. Kaur in the OSUCCC Department of Neurosurgery in the area of oncolytic virotherapy, with Dr. N. Ratner in the Division of Experimental Hematology & Cancer Biology at Cincinnati Children’s Research Foundation in the area of neurofibromatosis and malignant peripheral nerve sheath tumors, and with Dr. S. Wells in the Division of Hematology/Oncology at Cincinnati Children’s Research Foundation in the area of human papillomavirus-associated tumorigenesis.

Current Publications

  • Bolyard CM, Yoo JY, Wang PY, Saini U, Rath KS, Cripe TP, Zhang J, Selvendiran K, Kaur BDoxorubicin synergizes with 34.5ENVE to enhance antitumor efficacy against metastatic ovarian cancer.Clin Cancer Res in press 10/7/2014
  • Walterhouse DO, Pappo AS, Meza JL, Breneman JC, Hayes-Jordan AA, Parham DM, Cripe TP, Anderson JR, Meyer WH, Hawkins DSShorter-Duration Therapy Using Vincristine, Dactinomycin, and Lower-Dose Cyclophosphamide With or Without Radiotherapy for Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma: A Report From the Soft Tissue Sarcoma Committee of the Children's Oncology Group.J Clin Oncol in press 9/29/2014
  • Mazzacurati L, Marzulli M, Reinhart B, Miyagawa Y, Goins WF, Li A, Kaur B, Caligiuri M, Cripe T, Chiocca N, Amankulor N, Cohen JB, Glorioso JC, Grandi PUse of miRNA response sequences to block off-target replication and increase the safety of an unattenuated, glioblastoma-targeted oncolytic HSV.Mol Ther in press 9/9/2014
  • Streby KA, Shah N, Ranalli MA, Kunkler A, Cripe TPNothing but NET: A review of norepinephrine transporter expression and efficacy of (131) I-mIBG therapy.Pediatr Blood Cancer in press 8/30/2014
  • Yoo JY, Hurwitz BS, Bolyard C, Yu JG, Zhang J, Selvendiran K, Rath KS, He S, Bailey Z, Eaves D, Cripe TP, Parris DS, Caligiuri MA, Yu J, Old M, Kaur BBortezomib-induced unfolded protein response increases oncolytic HSV-1 replication resulting in synergistic antitumor effects.Clin Cancer Res 20 3787-98 7/15/2014
  • Wagner LM, Yin H, Eaves D, Currier M, Cripe TPPreclinical evaluation of nanoparticle albumin-bound paclitaxel for treatment of pediatric bone sarcoma.Pediatr Blood Cancer in press 4/19/2014
  • Brundage ME, Tandon P, Eaves DW, Williams JP, Miller SJ, Hennigan RH, Jegga A, Cripe TP, Ratner NMAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.Oncogene in press 2/10/2014
  • Wu J, Patmore DM, Jousma E, Eaves DW, Breving K, Patel AV, Schwartz EB, Fuchs JR, Cripe TP, Stemmer-Rachamimov AO, Ratner NEGFR-STAT3 signaling promotes formation of malignant peripheral nerve sheath tumors.Oncogene 33 173-80 1/9/2014
  • Geller J, Wagner L, Turpin B, Nagarajan R, Weiss B, Cripe TPilot study of vincristine, oral irinotecan, and temozolomide (VOIT regimen) combined with bevacizumab in pediatric patients with recurrent solid tumors or brain tumors.Pediatr Blood Cancer 60 1447-51 9/1/2013
  • Stehn JR, Haass NK, Bonello T, Desouza M, Kottyan G, Treutlein H, Zeng J, Nascimento PR, Sequeira VB, Butler TL, Allanson M, Fath T, Hill TA, McCluskey A, Schevzov G, Palmer SJ, Hardeman EC, Winlaw D, Reeve VE, Dixon I, Weninger W, Cripe TP, Gunning PWA novel class of anticancer compounds targets the actin cytoskeleton in tumor cells.Cancer Res 73 5169-82 8/15/2013
  • Wang PY, Currier MA, Hansford L, Kaplan D, Chiocca EA, Uchida H, Goins WF, Cohen JB, Glorioso JC, van Kuppevelt TH, Mo X, Cripe TPExpression of HSV-1 receptors in EBV-associated lymphoproliferative disease determines susceptibility to oncolytic HSV.Gene Ther 20 761-9 7/1/2013
  • Currier MA, Eshun FK, Sholl A, Chernoguz A, Crawford K, Divanovic S, Boon L, Goins WF, Frischer JS, Collins MH, Leddon JL, Baird WH, Hendrickson BW, Brekken RA, Kaur B, Hildeman D, Cripe TP, Haseley A, Streby KA, Wang PYVEGF blockade enables oncolytic cancer virotherapy in part by modulating intratumoral myeloid cells.Mol Ther 21 1014-23 5/1/2013
  • Jessen WJ, Miller SJ, Jousma E, Wu J, Rizvi TA, Brundage ME, Eaves D, Widemann B, Kim MO, Dombi E, Sabo J, Hardiman Dudley A, Niwa-Kawakita M, Page GP, Giovannini M, Aronow BJ, Cripe TP, Ratner NMEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors.J Clin Invest 123 340-7 1/2/2013

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) 460 W. 10th Avenue, Columbus, OH 43210 Phone: 1-800-293-5066 | Email: jamesline@osumc.edu